A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.
Scientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer's disease, and improve symptoms of neurodegeneration in mice.